1. Home
  2. ENTX vs MIST Comparison

ENTX vs MIST Comparison

Compare ENTX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.96

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.90

Market Cap

146.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
MIST
Founded
2010
2003
Country
Israel
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
146.9M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
ENTX
MIST
Price
$2.96
$0.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$9.00
$8.00
AVG Volume (30 Days)
344.3K
1.4M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.22
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
$2,915.14
Revenue Next Year
N/A
N/A
P/E Ratio
$13.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.88
52 Week High
$4.20
$3.06

Technical Indicators

Market Signals
Indicator
ENTX
MIST
Relative Strength Index (RSI) 49.83 31.89
Support Level $2.73 N/A
Resistance Level $3.10 $1.42
Average True Range (ATR) 0.19 0.06
MACD -0.02 -0.02
Stochastic Oscillator 46.81 5.29

Price Performance

Historical Comparison
ENTX
MIST

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

Share on Social Networks: